Hidroclorotiazida Stada (Hydrochlorothiazide)

Hydroclorotiazida Stada is indicated for several conditions where reduction of fluid overload or blood pressure control is required.

• Hypertension (high blood pressure) management, often as part of combination therapy.
• Edema associated with congestive heart failure, helping to remove excess fluid.
• Edema related to liver cirrhosis, reducing abdominal and peripheral swelling.
• Edema secondary to renal disease, facilitating sodium and water excretion.
• Occasionally used in the treatment of calcium‑containing kidney stones (off‑label).

• Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting the sodium‑chloride symporter (Na⁺/Cl⁻ cotransporter). This blockade reduces reabsorption of sodium and chloride, leading to increased urinary excretion of these ions together with water. The resulting decrease in extracellular fluid volume lowers cardiac output and systemic vascular resistance, contributing to its antihypertensive effect.

Like other thiazide diuretics, Hydroclorotiazida Stada may cause a range of adverse reactions, most of which are mild and reversible.

Common

• Increased urination (polyuria) and mild thirst.
• Low blood potassium (hypokalemia) presenting as muscle cramps or fatigue.
• Slight rise in blood glucose levels, especially in diabetic patients.
• Elevated blood uric acid that can precipitate gout attacks.

Serious

• Severe electrolyte disturbances such as hyponatremia or hypokalemia requiring medical attention.
• Acute kidney injury manifested by sudden decrease in urine output and rising creatinine.
• Allergic reactions including rash, itching, or angioedema.

Before starting Hydroclorotiazida Stada, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess baseline renal function and serum electrolytes, especially potassium and sodium.
• Review history of gout, diabetes, or hepatic impairment.
• Use caution in patients with known hypersensitivity to thiazide diuretics.
• Monitor blood pressure closely during initial therapy to avoid excessive hypotension.
• Consider dose adjustment in elderly patients due to altered pharmacokinetics.
• Avoid abrupt discontinuation, which may cause fluid retention.
• Counsel women who are pregnant or breastfeeding, as safety data are limited.

Hydroclorotiazida Stada can alter the pharmacokinetics or pharmacodynamics of several other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with other potent diuretics (e.g., loop diuretics) may cause excessive fluid and electrolyte loss.
• Co‑administration with lithium can increase lithium concentrations and risk of toxicity.
• Combining with non‑steroidal anti‑inflammatory drugs (NSAIDs) may blunt diuretic efficacy and worsen renal function.

Use with caution

• ACE inhibitors, ARBs, or beta‑blockers may enhance antihypertensive effect, requiring blood pressure monitoring.
• Antidiabetic agents may need dose adjustment due to possible rise in blood glucose.
• Digoxin levels can rise when potassium falls; monitor serum potassium and digoxin concentrations.